Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to Gefitinib

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Pinton, Giulia ^a   Thomas, Warren ^b   Bellini, Paolo ^a   Manente, Arcangela Gabriella ^a   Favoni, Roberto E ^c   Harvey, Brian J ^b   Mutti, Luciano ^d   Moro, Laura ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF GENOA   (Italy)

^d Local Health Unit 11   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CAVEOLIN 1; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR BETA; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TUBULIN; EPIDERMAL GROWTH FACTOR; MAPK1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACTIN POLYMERIZATION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; EPITHELIOID CELL; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; MALIGNANT MESOTHELIOMA; PHENOTYPE; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOPRECIPITATION; MESOTHELIOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PLEURA TUMOR; PROTEIN BINDING; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CAVEOLIN 1; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR BETA; HUMANS; IMMUNOPRECIPITATION; MESOTHELIOMA; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PLEURAL NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE;

EID: 78649751455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014110     Document Type: Article

References (40)

1. Yang H, Testa JR, Carbone M (2008) Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 9: 147-57. Review.
2. Pass HI, Carbone M (2009) Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21: 97-104.
3. Richards WG (2009) Recent advances in mesothelioma staging. Semin Thorac Cardiovasc Surg 21: 105-10.
4. Steele JP (2005) Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 19: 1041-52. Review.
5. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, et al. (2009) Oestrogen receptor b impacts on prognosis of human malignant mesothelioma. Cancer Res 69: 4598-604.
6. Ascenzi P, Bocedi A, Marino M (2006) Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 27: 299-402. Review.
7. Pettersson K, Gustafsson JA (2001) Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 63: 165-92.
8. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, et al. (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 98: 6330-5.
9. Erlandsson MC, Ohlsson C, Gustafsson JA, Carlsten H (2001) Role of oestrogen receptors alpha and beta in immune organ development and in oestrogenmediated effects on thymus. Immunology 103: 17-25.
10. Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, et al. (2006) Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A 103: 2959-64.
11. Wang L, Andersson S, Warner M, Gustafsson JA (2001) Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci U S A 98: 2792-6.
12. Marino M, Ascenzi P, Acconcia F (2006) S-palmitoylation modulates estrogen receptor alpha localization and functions. Steroids 71: 298-303. Review.
13. Marino M, Ascenzi P (2008) Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation. Steroids 73: 853-8. Review.
14. Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 3: 309-17. Review.
15. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, et al. (2005) Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65: 10585-93.
16. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, et al. (2006) Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 1089: 194-200.
17. Filardo EJ, Quinn JA, Frackelton Jr. AR, Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16: 70-84.
18. Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J (1998) Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55: 5-10. Review.
19. Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, et al. (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signaling pathways. Genes Cells 5: 593-601. Review.
20. Sanchez M, Picard N, Sauvé K, Tremblay A (2010) Challenging estrogen receptor beta with phosphorylation. Trends Endocrinol Metab 21: 104-110.
21. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, et al. (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51: 207-15.
22. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ (2006) EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54: 399-407.
23. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, et al. (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25: 2406-13.
24. Govindan R, Kratzke RA, Herndon JE, 2nd, Niehans GA, Vollmer R, et al. (2005) Gefitinib in patients with malignant mesothelioma: a phase II study. Clin Cancer Res 11: 2300-4.
25. Aguilar RC, Wendland B (2005) Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci U S A 102: 2679-80.
26. Couet J, Sargiacomo M, Lisanti MP (1997) Interaction of a receptor tyrosine kinase, EGFR, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-38.
27. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, et al. (2004) EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 112: 78-86.
28. Fukuoka M, Yano S, Giaccone G, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-smallcell lung cancer. J Clin Oncol 21: 2237-46.
29. Arteaga CL (2003) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122-30.
30. Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-500.
31. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB (2006) Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118(2): 521-2.
32. Zhao C, Dahlman-Wright K, Gustafsson JA (2008) Estrogen receptor b: an overview and update. Nucl Recept Signal 6: 1-10.
33. Moggs JG, Orphanides G (2001) Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep 2: 775-81.
34. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, et al. (2009) Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 69: 6100-6.
35. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865-70. Review.
36. Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-33. Review.
37. Fagan DH, Yee D (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13: 423-9. Review.
38. Smythe WR, Kaiser LR, Hwang HC, et al. (1994) Successful adenovirusmediated gene transfer in an in vivo model of human malignant mesothelioma. The Annals of Thoracic Surgery 57: 1395-1401.
39. Bepler G, et al. (1988) Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37: 158-171.
40. Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, et al. (2007) Induction of Tumorigenesis and Metastasis by the Murine Orthologue of Tumor Protein. Mol Cancer Res 5: 133-44.